Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
107 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Brain Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Brain Cancer - Pipeline Review, H2 2014', provides an overview of the Brain Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Brain Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Brain Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Brain Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Brain Cancer Overview 8 Therapeutics Development 9 Pipeline Products for Brain Cancer - Overview 9 Pipeline Products for Brain Cancer - Comparative Analysis 10 Brain Cancer - Therapeutics under Development by Companies 11 Brain Cancer - Therapeutics under Investigation by Universities/Institutes 13 Brain Cancer - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Brain Cancer - Products under Development by Companies 16 Brain Cancer - Products under Investigation by Universities/Institutes 17 Brain Cancer - Companies Involved in Therapeutics Development 18 Neuralstem, Inc. 18 Bionomics Limited 19 Critical Outcome Technologies Inc. 20 Prana Biotechnology Limited 21 e-Therapeutics plc 22 AngioChem Inc. 23 Merrimack Pharmaceuticals, Inc. 24 Stemline Therapeutics, Inc. 25 Kinex Pharmaceuticals, LLC 26 Nuvilex, Inc. 27 TAU Therapeutics, LLC 28 CureFAKtor Pharmaceuticals. LLC 29 Arrien Pharmaceuticals, LLC 30 Oncology Research International Limited 31 Brain Cancer - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 36 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Drug Profiles 43 pritumumab - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 dexanabinol - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 MDNA-55 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 KX-02 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 COTI-2 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 irinotecan sucrosofate liposomal - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 SL-302 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 BNC-105 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 ANG-1007 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 TTL-1177 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 CFAK-C4 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 NSI-566 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 KX-02 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 CFAKY-15 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 PBT-519 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 ARN-7016 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Vaccine for Brain Cancer and Glioblastoma Multiforme - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 imipramine blue nanocarrier - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 ORIL-007 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Methoxynaphthylfenoterol - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 SL-301 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Cannabidiol For Pancreatic Cancer And Brain Cancer - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Small Molecule for Brain Cancer - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Brain Cancer - Recent Pipeline Updates 74 Brain Cancer - Dormant Projects 96 Brain Cancer - Discontinued Products 97 Brain Cancer - Product Development Milestones 98 Featured News & Press Releases 98 Jul 01, 2014: Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis 98 May 15, 2014: Diffusion Pharmaceuticals Clinical Trial of TSC in Brain Cancer Reaches One Year Interim Endpoint 99 May 08, 2014: e-Therapeutics announces recruitment resumes into US phase I ETS2101 brain cancer trial 99 Apr 08, 2014: ZIOPHARM Presents Preclinical Data at AACR Annual Meeting Supporting Controlled DNA-based IL-12 Therapy for Brain Cancer 100 Mar 07, 2014: NW Bio Receives Recommendation to Continue with Phase III GBM Brain Cancer Trial Based On Data Safety Monitoring Board's Safety Review 101 Jan 07, 2014: e-Therapeutics provides update on ETS2101 phase I trial in brain cancer 101 Dec 16, 2013: Positive Phase 2 Results from Agenus' Brain Cancer Vaccine Published in Neuro-Oncology 102 Nov 25, 2013: NewGen Therapeutics Reports Potent Anticancer Activity for Targeted Brain Cancer Drug, NT-113 103 Oct 21, 2013: Angiochem Initiates Phase 2 Clinical Study for Lead Drug Candidate, ANG1005, in Primary Brain Cancer 103 Sep 26, 2013: to-BBB Presents Clinical Data on Lead Product 2B3-101 104 Appendix 106 Methodology 106 Coverage 106 Secondary Research 106 Primary Research 106 Expert Panel Validation 106 Contact Us 107 Disclaimer 107
List of Tables Number of Products under Development for Brain Cancer, H2 2014 9 Number of Products under Development for Brain Cancer - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Products under Investigation by Universities/Institutes, H2 2014 17 Brain Cancer - Pipeline by Neuralstem, Inc., H2 2014 18 Brain Cancer - Pipeline by Bionomics Limited, H2 2014 19 Brain Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2014 20 Brain Cancer - Pipeline by Prana Biotechnology Limited, H2 2014 21 Brain Cancer - Pipeline by e-Therapeutics plc, H2 2014 22 Brain Cancer - Pipeline by AngioChem Inc., H2 2014 23 Brain Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 24 Brain Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2014 25 Brain Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H2 2014 26 Brain Cancer - Pipeline by Nuvilex, Inc., H2 2014 27 Brain Cancer - Pipeline by TAU Therapeutics, LLC, H2 2014 28 Brain Cancer - Pipeline by CureFAKtor Pharmaceuticals. LLC, H2 2014 29 Brain Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 30 Brain Cancer - Pipeline by Oncology Research International Limited, H2 2014 31 Assessment by Monotherapy Products, H2 2014 32 Number of Products by Stage and Target, H2 2014 35 Number of Products by Stage and Mechanism of Action, H2 2014 38 Number of Products by Stage and Route of Administration, H2 2014 40 Number of Products by Stage and Molecule Type, H2 2014 42 Brain Cancer Therapeutics - Recent Pipeline Updates, H2 2014 74 Brain Cancer - Dormant Projects, H2 2014 96 Brain Cancer - Discontinued Products, H2 2014 97
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.